Genomics Services
 
 
Tamoxifen
Tamoxifen is an antagonist of Estrogen Receptors (ER). Tamoxifen is widely used in antiestrogen therapy for pre-and postmenopausal women with metastatic breast cancer. Tamoxifen metabolism is regulated by the enzymes encoded by CYP2D6 genes. Polymorphism in CYP2D6 genes causes alteration in expression levels that is associated with enzyme levels. Genotype guided tamoxifen administration may be benificial for breast cancer patients to optimize trailored treatment.

Sample Type

FFPE Tissue Formalin Fixed Parafin Embedded (FFPE) tissue block with atleast 3-4 sections of tumor tissue. Tissue section should contain >70% tumor content verified by pathologist and should be sent along with 5 H&E stained and 5 unstained slides of tumor tissue.
 
Brochure           inquiry
 
 
EGFR (Epidermal Growth Factor Receptor)   |   ALK (Anaplastic lymphoma kinase)
BRAF (B-Raf proto-oncogene, serine/threonine kinase)   |   BRCA1 and BRCA2   |   CHECK2 (Check Point Homolog)
KRAS (Ki-ras2 Kirsten rat sarcoma viral oncogene homolog)   |   Tyrosine Kinase Sensitivity for KIT & PDGFRA
HER2 (Human Epidermal Growth factor Receptor 2) or ERBB2   |   TP53 (Tumor Protein p53)   |   BCR-ABL
Tamoxifen   |   NRAS Mutation   |   Tyrosine Kinase Sensitivity for Abl1 Mutations
HRAS Mutation (Harvey rat sarcoma viral Oncogene Homolog)   |   DPYD Mutation (for 5FU Sensitivity)
MAPK1 Mutation Analysis
 
 
Click Here to Zoom
 
Click Here to Zoom
 
Click Here to Zoom
 
Click Here to Zoom